Donald Macarthur and Dr. Meriem Bouslouk-Marx discuss post-approval findings of national committees in Europe charged with deciding the best strategy to use a new COVID-19 vaccine in their populations.
Donald Macarthur and Dr. Meriem Bouslouk-Marx
Advertisement
Donald Macarthur is an independent global pharmaceutical business analyst. Dr. Meriem Bouslouk-Marx is independent adviser at MBM Future Health.
Articles by Donald Macarthur and Dr. Meriem Bouslouk-Marx
Advertisement
Latest Updated Articles
- Efficacy Controversy Hits European COVID-19 Vaccine Rollout
Published: February 16th 2021 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Johnson and Johnson Reveals Plan to Separate Orthopaedics Business
2
The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
3
The Evolving Landscape in Psychiatry: Challenges and Opportunities for Biopharma
4
Nabla Bio Enters $1 Billion Multi-Year Research Collaboration with Takeda
5
